Literature DB >> 20006692

Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect.

Kiyohiko Sugano1.   

Abstract

According to the present theory of oral absorption, in the case of solubility limited absorption, the absorbed amount would not increase despite an increase in dose or a decrease in particle size. However, many experimental observations suggested that the absorbed amount was often increased (though sub-proportionally) as the dose strength increased. In addition, the particle size reduction was often effective to increase the absorbed amount even in the case of solubility limited absorption. Since an increase of the dose strength and a decrease of the particle size cause no or little change in solubility and the mean intestinal transit time, effective intestinal membrane permeability (P(eff)) should have changed. The previous theory postulated that drug particles do not exist in the unstirred water layer (UWL) which is adjacent to the intestinal membrane. However, many reports suggested that nano- to micro-scale drug particles existed in the UWL. In this case, the effective thickness of the UWL (h(eff)) could be smaller than the nominal thickness, resulting in an increase of P(eff). In the present study, h(eff) was simply calculated assuming that the reduction of h(eff) is in proportion to the surface area of drug particles in the UWL. When the particle drifting effect was taken into account, the discrepancy between the theoretical calculation and experimental observations was reduced. It was suggested that when the dose (mg)/particle diameter (microm) ratio exceeds 20, the particle drifting effect would become significant. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006692     DOI: 10.1016/j.ijpharm.2009.12.014

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

Review 1.  Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds.

Authors:  Filippos Kesisoglou; Amitava Mitra
Journal:  AAPS J       Date:  2012-06-27       Impact factor: 4.009

2.  Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.

Authors:  Filippos Kesisoglou
Journal:  AAPS PharmSciTech       Date:  2014-02       Impact factor: 3.246

3.  Ranking Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane.

Authors:  Konstantin Tsinman; Oksana Tsinman; Ram Lingamaneni; Saijie Zhu; Bernd Riebesehl; Arnaud Grandeury; Michael Juhnke; Bernard Van Eerdenbrugh
Journal:  Pharm Res       Date:  2018-06-20       Impact factor: 4.200

Review 4.  Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?

Authors:  Kaijie Qian; Lorenzo Stella; David S Jones; Gavin P Andrews; Huachuan Du; Yiwei Tian
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

5.  Lost in modelling and simulation?

Authors:  Kiyohiko Sugano
Journal:  ADMET DMPK       Date:  2021-03-22

Review 6.  Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models.

Authors:  David Dahlgren; Erik Sjögren; Hans Lennernäs
Journal:  ADMET DMPK       Date:  2020-09-17

7.  Non-Effective Improvement of Absorption for Some Nanoparticle Formulations Explained by Permeability under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

8.  Mechanisms and Extent of Enhanced Passive Permeation by Colloidal Drug Particles.

Authors:  Akshay Narula; Rayan Sabra; Na Li
Journal:  Mol Pharm       Date:  2022-08-23       Impact factor: 5.364

9.  Dose-Dependent Solubility-Permeability Interplay for Poorly Soluble Drugs under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2021-03-02       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.